eoadjuvant radiation therapy concurrent with S-1 followed by systemic S-1/Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A pilot study - The pilot study of neoadjuvant S1+RT followed by systemic GS therapy for Borderline resectable pancreatic cancer patients

Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Hospital0 sites30 target enrollmentSeptember 14, 2012

Overview

Phase: 未知
Intervention: Not specified
Conditions: pancreatic cancer
Sponsor: Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Hospital
Enrollment: 30
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

September 14, 2012

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Hospital

•1\) Patients who have previously administered S\-1 or gemcitabine 2\) Patients who have previous history of radiotherapy to the abdomen 3\) Uncontrollable watery or chornic diarrhea 4\) Regular use of frucitocin, fenitoin or warfarin 5\) Patients who can' t receive neither iodic drug because of drug allergy 6\) Lung fibrosis or interstitial pneumonia which accompanied by clinical symptoms or are evident in imaging findings 7\) Massive pleural or abdominal effusion 8\) Those with Active infectious diseases 9\) Uncontrolled diabetes 10\) Simultaneous or metachronous (within 3 years) double cancers 11\) Hemorrhagic peptic ulcer 12\) Severe complications 13\) Patients requiring systemic steroids medication 14\) Severe mental disorders 15\) Severe drug hypersensitivity 16\) Pregnant or lactating women, or women with known or suspected pregnancy and men who want let to pregnancy 17\) Patients seems inadequate for this study by investigators 18\) Treatment history of a collagen disease or undergoing medical treatment